Discounted Cash Flow (DCF) Analysis Unlevered

Pharmasimple SA (ALPHS.PA)

0.0001 €

0.00 (0.00%)
All numbers are in Millions, Currency in USD
Stock DCF: 416.19 | 0.0001 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 19.1717.1328.6546.4764.8890.57126.45176.53246.44
Revenue (%)
EBITDA -0.99-1.56-1.540.41-3.04-4.25-5.93-8.28-11.56
EBITDA (%)
EBIT -1.31-1.84-2.02-0.37-4.14-5.77-8.06-11.25-15.71
EBIT (%)
Depreciation 0.320.290.480.781.091.532.132.974.15
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Total Cash 3.823.415.719.2612.9318.0425.1935.1749.10
Total Cash (%)
Account Receivables ---------
Account Receivables (%)
Inventories 3.783.494.624.9710.8615.1721.1729.5641.27
Inventories (%)
Accounts Payable 4.563.945.387.5413.2618.5225.8536.0950.39
Accounts Payable (%)
Capital Expenditure ---------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 0.0,001
Beta 1.535
Diluted Shares Outstanding 2.89
Cost of Debt
Tax Rate 0.93
After-tax Cost of Debt 1.31%
Risk-Free Rate
Market Risk Premium
Cost of Equity 10.738
Total Debt 7.89
Total Equity 0
Total Capital 7.90
Debt Weighting 100.00
Equity Weighting 0.00
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue 19.1717.1328.6546.4764.8890.57126.45176.53246.44
EBITDA -0.99-1.56-1.540.41-3.04-4.25-5.93-8.28-11.56
EBIT -1.31-1.84-2.02-0.37-4.14-5.77-8.06-11.25-15.71
Tax Rate -0.00%-0.00%0.31%0.93%0.31%0.31%0.31%0.31%0.31%
EBIAT -1.31-1.84-2.02-0.37-4.12-5.76-8.03-11.22-15.66
Depreciation 0.320.290.480.781.091.532.132.974.15
Accounts Receivable ---------
Inventories -0.29-1.13-0.35-5.89-4.30-6.01-8.39-11.71
Accounts Payable --0.621.442.165.725.257.3310.2414.29
Capital Expenditure ---------
UFCF --1.88-1.222.23-3.20-3.28-4.58-6.39-8.92
WACC
PV UFCF -3.20-3.24-4.46-6.15-8.47
SUM PV UFCF -25.18

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 1.31
Free cash flow (t + 1) -9.10
Terminal Value 1,318.77
Present Value of Terminal Value 1,235.68

Intrinsic Value

Enterprise Value 1,210.50
Net Debt 7.89
Equity Value 1,202.61
Shares Outstanding 2.89
Equity Value Per Share 416.19